Capsugel and Pulmatrix Collaborate on Pulmonary Disease Treatments

February 17, 2016
BioPharm International Editors

The collaboration will allow the companies to develop and manufacture novel inhaled therapeutics.

Capsugel and Pulmatrix formed a collaboration to develop and manufacture novel inhaled therapeutics for pulmonary diseases, according to a Feb. 16, 2016 press announcement from the companies. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE -based inhaled therapeutic candidates being developed by Pulmatrix and its potential development partners.

iSPERSE is a dense and dispersible-engineered particle technology that enables pulmonary delivery of drugs with high delivery efficiency, dose reproducibility, and flow-rate independence. Several products leveraging the iSPERSE platform are in development, two of which are a clinical stage bronchodilator (PUR0200) for chronic obstructive pulmonary disease, and an inhaled anti-fungal (PUR1900) for cystic fibrosis.

“This collaboration provides us with access to Capsugel’s spray dry technology, scale-up capabilities, and state-of-the-art equipment to support our growing pipeline of internal and partnered development programs,” said Robert Clarke, PhD, CEO of Pulmatrix in a press announcement.

Source: Capsugel